1-hexadecyl-2-acetyl-glycero-3-phosphocholine has been researched along with sevoflurane in 1 studies
| Studies (1-hexadecyl-2-acetyl-glycero-3-phosphocholine) | Trials (1-hexadecyl-2-acetyl-glycero-3-phosphocholine) | Recent Studies (post-2010) (1-hexadecyl-2-acetyl-glycero-3-phosphocholine) | Studies (sevoflurane) | Trials (sevoflurane) | Recent Studies (post-2010) (sevoflurane) |
|---|---|---|---|---|---|
| 9,156 | 187 | 552 | 7,131 | 2,150 | 3,238 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Crystal, GJ; Hu, G; Rhone, DP; Salem, MR; Vasiliauskas, T | 1 |
1 other study(ies) available for 1-hexadecyl-2-acetyl-glycero-3-phosphocholine and sevoflurane
| Article | Year |
|---|---|
Neutrophils pretreated with volatile anesthetics lose ability to cause cardiac dysfunction.
Topics: Anesthetics, Inhalation; Animals; Coronary Circulation; Dose-Response Relationship, Drug; Endothelium, Vascular; Female; Ischemic Preconditioning, Myocardial; Isoflurane; Male; Methyl Ethers; Myocardial Contraction; Neutrophils; Platelet Activating Factor; Rats; Rats, Sprague-Dawley; Sevoflurane; Superoxides | 2003 |